Obsidian Therapeutics, Inc. Common Stock Asset Resilience Ratio
Obsidian Therapeutics, Inc. Common Stock asset resilience ratio. Obsidian Therapeutics, Inc. Common Stock (OBX) has an Asset Resilience Ratio of 46.08% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Obsidian Therapeutics, Inc. Common Stock (OBX) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Obsidian Therapeutics, Inc. Common Stock (2024–2025)
Asset resilience ratio of Obsidian Therapeutics, Inc. Common Stock from 2024 to 2025. This chart shows how Obsidian Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See OBX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Obsidian Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Obsidian Therapeutics, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $32.32 Million | 46.08% |
| Total Liquid Assets | $32.32 Million | 46.08% |
Asset Resilience Insights
- Very High Liquidity: Obsidian Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 46.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Obsidian Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Obsidian Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Obsidian Therapeutics, Inc. Common Stock Asset Resilience Ratio by Year (2024–2025)
Obsidian Therapeutics, Inc. Common Stock asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for Obsidian Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 45.25% | $40.08 Million | $88.58 Million | -19.26pp |
| 2024-12-31 | 64.51% | $118.51 Million | $183.71 Million | -- |
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform de… Read more